A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients

Excelsior48 enrolled

Overview

This is a retrospective study to assess the clinical efficacy and safety of trientine in Wilson's disease patients

In this retrospective study, the investigators will collect and analyze data from reviewing medical history files of larger and long-term follow-up cohorts with Wilson's disease in Taiwan to assess the efficacy and safety of Trientine in Taiwanese Wilson's Disease patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Trientine Treatment for Wilson's Disease

Interventions

TrientineDRUG

Trientine is a chelating agent for removing the copper from the body

Eligibility

Sex: ALLMin age: 3 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of Wilson's disease. * Male or female patients, aged 3 years to 75 years Exclusion Criteria: * Patients with comorbidity which is not related to Wilson's disease.

Locations (1)

Chang Gung Memorial Hospital, Linkou

Taoyuan, Taiwan

Outcomes

Primary Outcomes

The improvement in liver function

To measure the AST (aspartate aminotransferase), ALT (alanine transaminase), GGT (gamma-glutamyl transpeptidase), Albumin, and Bilirubin level, and compare to the baseline

Time frame: Up to 1 year

Secondary Outcomes

The improvement in urine copper excretion

To measure 24-hour urine copper levels during the study period

Time frame: Up to 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.